
Cardiol Therapeutics (CRDL) Stock Forecast & Price Target
Cardiol Therapeutics (CRDL) Analyst Ratings
Bulls say
Cardiol Therapeutics is expected to be successful in their development of CardiolRx due to strong peer-reviewed Phase II data supporting its oral use, quick and lasting response in relieving recurring pericarditis pain, and potential for use as an oral steroid-sparing option. The company also has a strong financial standing with enough cash to fund operations into 3Q27 and a high success probability for CardiolRx in the recurrent pericarditis market.
Bears say
Cardiol Therapeutics is currently focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. However, their current success may be limited by challenging and commercially relevant questions surrounding their flagship drug, CardiolRx. While their Phase II findings provide a strong biological basis, success in their ongoing Phase III trial will depend on several key factors, including the placebo recurrence rate and the absolute treatment effect. Additionally, CardiolRx may need to demonstrate comparable anti-inflammatory effects to other available treatments in order to have a significant commercial opportunity. Overall, the outcome of their Phase III trial will be a crucial factor in determining the company's potential success in the near future.
This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cardiol Therapeutics (CRDL) Analyst Forecast & Price Prediction
Start investing in Cardiol Therapeutics (CRDL)
Order type
Buy in
Order amount
Est. shares
0 shares